Extracorporeal photopheresis in cutaneous T-cell lymphoma. Inconsistent data underline the need for randomized studies

British Journal of Dermatology

Volumn 142, Issue 1, 2000, Pages 16-21

  Russell Jones, R ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Cutaneous T cell lymphoma; Extracorporeal photopheresis; Response rates; Sezary syndrome; Survival data; T cell receptor gene analysis

Indexed keywords

METHOXSALEN;

ADULT; ANTIGENICITY; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLONAL ANERGY; DRUG EFFECT; ERYTHRODERMA; FEMALE; HUMAN; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PUVA; RECEPTOR GENE; SEZARY SYNDROME; SKIN CANCER; T CELL LYMPHOMA; T LYMPHOCYTE SUBPOPULATION; ULTRAVIOLET A RADIATION;

HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; PHOTOPHERESIS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ANTIGEN, T-CELL; SEZARY SYNDROME; SURVIVAL ANALYSIS;

EID: 0033971149     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2000.03286.x     Document Type: Article

References (39)

1. Lutzner M, Edelson R, Scheir P et al. Cutaneous T-cell lymphoma: the Sézary syndrome, mycosis fungoides and related disorders. Ann Intern Med 1975; 83: 534-52.
2. Kim YH, Varghese A, Hoppe RT. Prognostic factors in erythrodermic mycosis fungoides and the Sézary syndrome. Arch Dermatol 1995; 131: 1003-8.
3. Weiss LM, Wood GS, Hu E et al. Detection of clonal T-cell receptor gene rearrangements in the peripheral blood of patients with mycosis fungoides/Sézary syndrome. J Invest Dermatol 1989; 92: 601-4.
4. Whittaker S, Smith NP, Russell-Jones R, Luzzatto L. Analysis of β, γ and δ T-cell receptor genes in mycosis fungoides and Sézary syndrome. Cancer 1991; 68: 1572-82.
5. Fraser-Andrews EA, Wolstencroft R, Dean A et al. TCR gene analysis of peripheral blood defines 2 distinct subsets in Sézary syndrome. Br J Dermatol 1998; 139 (Suppl. 51): 29(Abstr.).
6. Russell-Jones R, Whittaker S. TCR gene analysis in the diagnosis of Sézary syndrome. J Am Acad Dermatol 1999; 41: 254-9.
7. Edelson R, Berger C, Gasparro F et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy: preliminary results. N Engl J Med 1987; 316: 297-303.
8. Heald PW, Perez MI, Christensen I et al. Photopheresis therapy of cutaneous T-cell lymphoma: the Yale-New Haven Hospital experience. Yale Biol Med 1989; 62: 629-38.
9. Edelson R, Perez MI, Heald PW, Berger C. Extracorporeal photochemotherapy. Biol Ther Cancer Updates 1994; 4: 1-12.
10. Hanlon DJ, Berger C, Edelson R. Photoactivated 8-methoxypsoralen treatment causes a peptide-dependent increase in antigen display by transformed lymphocytes. Int J Cancer 1998; 78: 70-5.
11. Gottlieb SL, Wolfe JT, Fox FE et al. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon-alpha: a 10 year experience at a single institution. J Am Acad Dermatol 1996; 35: 946-57.
12. Fraser-Andrews EA, Ng Y, Seed P et al. Detection of a peripheral blood clone as an independent marker in tumour stage mycosis fungoides using PCR/SSCP analysis of the T-cell receptor γ gene. J Invest Dermatol 1997; 109: 44.
13. Vowels B, Cassin M, Boufal M et al. Extracorporeal photochemotherapy induces the production of tumour necrosis factor-alpha by monocytes: implications for the treatment of cutaneous T-cell lymphoma and systemic sclerosis. J Invest Dermatol 1992; 98: 686-92.
14. Tharp M, Whiteside T, Charley M et al. In vitro sensitivity of Sézary cells to natural cytotoxicity. J Invest Dermatol 1989; 92: 531(Abstr.).
15. Koh HK, Davis BE, Meola T et al. Extracorporeal photopheresis for the treatment of 34 patients with cutaneous T-cell lymphoma (CTCL). J Invest Dermatol 1994; 102: 567 (Abstr.).
16. Stevens S, Masten S, Oberhelman-Bragg L et al. Circulating CD4+ CD7- lymphocyte burden, CD4+/CD8+ ratio and rapidity of response are predictors of outcome in the treatment of CTCL with extracorporeal photochemotherapy (ECP). Photodermatol Photoimmunol Photomed 1996; 12: 36 (Abstr.).
17. Duvic M, Hester JP, Lemak A. Photopheresis therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 1996; 35: 573-9.
18. Zic J, Stricklin G, Greer J et al. Long term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy. J Am Acad Dermatol 1996; 35: 935-45.
19. Russell-Jones R, Fraser-Andrews EA, Spittle M, Whittaker S. Extracorporeal photopheresis in Sézary syndrome. (Letter.) Lancet 1997; 350: 886.
20. Vonderheid EC, Zhang Q, Lessin S et al. Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma. J Am Acad Dermatol 1998; 38: 207-20.
21. Zachariae H, Bjerring P, Brodthagen U, Sogaard H. Photopheresis in the red man or pre-Sézary syndrome. Dermatology 1995; 190: 132-5.
22. Heald PW, Rook A, Perez MI et al. Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. J Am Acad Dermatol 1992; 27: 427-33.
23. Fraser-Andrews EA, Seed P, Whittaker S, Russell-Jones R. Extracorporeal photopheresis in Sézary syndrome: no significant effect in the survival of 44 patients with a peripheral blood T-cell clone. Arch Dermatol 1998; 134: 1001-5.
24. Edelson R. Sézary Syndrome, cutaneous T-cell lymphoma and extracorporeal photophoresis. (Letter.) Arch Dermatol 1999; 135: 600.
25. Edelson R. Invited lecture to the Annual Meeting of the British Association of Dermatologists. Glasgow, July 1995.
26. Russell-Jones R, Fraser-Andrews EA, Spittle M, Whittaker S. Sézary Syndrome, cutaneous T-cell lymphoma and extracorporeal photophoresis. (Reply.) Arch Dermatol 1999; 135: 600-1.
27. Ratnavel R, Ledger S, Forsdyke H et al. Trial of extracorporeal photochemotherapy (ECP) in erythrodermic cutaneous T-cell lymphoma (CTCL). Br J Dermatol 1996; 135 (Suppl. 47): 65-6.
28. Holloway K, Flowers F, Ramos-Caro F. Therapeutic alternatives in cutaneous T-cell lymphoma. J Am Acad Dermatol 1992; 27: 367-78.
29. Rosen ST, Foss FM. Chemotherapy for mycosis fungoides and the Sézary syndrome. Hematol Oncol Clin N Am 1995; 9: 1109-16.
30. Kemme DJ, Bunn PA. State of the art therapy of mycosis fungoides and Sézary syndrome. Oncology 1992; 6: 31-42.
31. Winkelmann RK, Diaz-Perez JL, Buechner SA. The treatment of Sézary syndrome. J Am Acad Dermatol 1984; 10: 1000-4.
32. Hamminga L, Hartgrink-Groeneveld CA, van Vloten WA. Sézary's syndrome: a clinical evaluation of eight patients. Br J Dermatol 1979; 100: 291-6.
33. Zackheim HS, Epstein EH. Low-dose methotrexate for the Sézary syndrome. J Am Acad Dermatol 1989; 21: 757-62.
34. Zackheim HS, Kashani-Sabet M, Hwang S. Low-dose methotrexate to treat erythrodermic cutaneous T-cell lymphoma. Results in 29 patients. J Am Acad Dermatol 1996; 34: 626-31.
35. Olsen EA, Bunn PA. Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin N Am 1995; 9: 1089-107.
36. Roenigk HH Jr, Kuzel TM, Skoutelis AP et al. Photochemotherapy alone or combined with interferon-alpha-2a in the treatment of cutaneous T-cell lymphoma. J Invest Dermatol 1990; 95 (Suppl. 6): 198-205S.
37. Kuzel TM, Roenigk HH Jr, Samuelson E et al. Effectiveness of interferon-alpha-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome. J Clin Oncol 1995; 13: 257-63.
38. Dippel E, Schragg H, Goerdt S, Orfanos CE. Extracorporeal photopheresis and interferon-alpha in advanced cutaneous T-cell lymphoma. Lancet 1997; 350: 32-3.
39. Zackheim HS, Whittaker S, Fraser-Andrews E. Assessing clinical outcomes in cutaneous T-cell lymphoma. Haematol Oncol N Am 1995; 9: 1021-9.